A citation-based method for searching scientific literature

Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, Christopher P Cannon, Bruce Neal, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull, George Capuano, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Tao Sun, David C Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Norman Rosenthal, Barry M Brenner, Vlado Perkovic. Circulation 2019
Times Cited: 128



Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing, C David Sjöström, Roberto D Toto, Anna-Maria Langkilde, David C Wheeler. N Engl J Med 2020
Times Cited: 884




List of shared articles



Times cited

Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
Jonatan Barrera-Chimal, Ixchel Lima-Posada, George L Bakris, Frederic Jaisser. Nat Rev Nephrol 2022
6

Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis.
Yuki Kawai, Kazushi Uneda, Takayuki Yamada, Sho Kinguchi, Kazuo Kobayashi, Kengo Azushima, Tomohiko Kanaoka, Yoshiyuki Toya, Hiromichi Wakui, Kouichi Tamura. Diabetes Res Clin Pract 2022
1

Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials.
Juan Jose Garcia Sanchez, Juliette Thompson, David A Scott, Rachel Evans, Naveen Rao, Elisabeth Sörstadius, Glen James, Stephen Nolan, Eric T Wittbrodt, Alyshah Abdul Sultan,[...]. Adv Ther 2022
1

11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022.
Boris Draznin, Vanita R Aroda, George Bakris, Gretchen Benson, Florence M Brown, RaShaye Freeman, Jennifer Green, Elbert Huang, Diana Isaacs, Scott Kahan,[...]. Diabetes Care 2022
10

Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis.
Ning Li, Guowei Zhou, Yawei Zheng, Dan Lv, Xiangjun Zhu, Ping Wei, Min Zheng, Shijia Liu, Enchao Zhou, Wei Sun,[...]. PLoS One 2022
0

Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect.
Savina Nodari, Francesco Fioretti, Francesco Barilla. Heart Fail Rev 2022
0

Kidney and heart failure outcomes associated with SGLT2 inhibitor use.
Annemarie B van der Aart-van der Beek, Rudolf A de Boer, Hiddo J L Heerspink. Nat Rev Nephrol 2022
2

Chronic kidney disease and vascular risk - what's new?
R Santamaría Olmo, M V Pendón Ruiz de Mier, C Rodelo Haad. Hipertens Riesgo Vasc 2022
0

Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage.
Bharathi Upadhya, Patrick M Kozak, Richard Brandon Stacey, Ramachandran S Vasan. Curr Hypertens Rep 2022
1

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Arnaud D Kaze, Min Zhuo, Seoyoung C Kim, Elisabetta Patorno, Julie M Paik. Cardiovasc Diabetol 2022
0

Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.
Anna Norhammar, Johan Bodegard, Jan W Eriksson, Hermann Haller, Gerard C M Linssen, Amitava Banerjee, Avraham Karasik, Pavlos Mamouris, Navdeep Tangri, Tiago Taveira-Gomes,[...]. Diabetes Obes Metab 2022
0

Effects of an SGLT Inhibitor on the Production, Toxicity, and Elimination of Gut-Derived Uremic Toxins: A Call for Additional Evidence.
Pieter Evenepoel, Bjorn Meijers, Rosalinde Masereeuw, Jerome Lowenstein. Toxins (Basel) 2022
0


Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita,[...]. Cardiovasc Diabetol 2022
0

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Jaime Blais, Qiang Li, Meg J Jardine,[...]. Am J Kidney Dis 2021
19

Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
Chin Meng Khoo, Chaicharn Deerochanawong, Siew Pheng Chan, Bien Matawaran, Wayne Huey-Herng Sheu, Juliana Chan, Ambrish Mithal, Andrea Luk, Ketut Suastika, Kun-Ho Yoon,[...]. Diabetes Obes Metab 2021
4

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
John J V McMurray, David C Wheeler, Bergur V Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Claes Held, Fan-Fan Hou,[...]. Circulation 2021
32

Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
Ronald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, Jeremy D Gilbert, Megha Poddar, Subodh Verma. Can J Diabetes 2021
4

Prediction models and nomograms for 10-year risk of end-stage renal disease in Chinese type 2 diabetes mellitus patients in primary care.
Weinan Dong, Eric Yuk Fai Wan, Daniel Yee Tak Fong, Ruby Lai Ping Kwok, David Vai Kiong Chao, Kathryn Choon Beng Tan, Eric Ming Tung Hui, Wendy Wing Sze Tsui, King Hong Chan, Colman Siu Cheung Fung,[...]. Diabetes Obes Metab 2021
3

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Hirotaka Miyashita, Takahisa Mikami, Hiroki Ueyama, Tomohiro Fujisaki, Yusuke Saigusa, Takahiro Yamaji,[...]. Cardiovasc Diabetol 2021
22

Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin.
Ricardo Fontes-Carvalho, Diogo Santos-Ferreira, Itamar Raz, Nikolaus Marx, Frank Ruschitzka, Francesco Cosentino. Eur J Prev Cardiol 2021
8

Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.
Takashi Kadowaki, Fumiko Yamamoto, Yusuke Taneda, Yusuke Naito, Douglas Clark, Søren S Lund, Tomoo Okamura, Kohei Kaku. Expert Opin Drug Saf 2021
1

Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.
Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J L Heersprink, Mikhail Kosiborod, Christoph Wanner, Eberhard Standl. Cardiovasc Diabetol 2021
3


Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
6

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Thomas A Zelniker, Itamar Raz, Ofri Mosenzon, Jamie P Dwyer, Hiddo H J L Heerspink, Avivit Cahn, Erica L Goodrich, Kyungah Im, Deepak L Bhatt, Lawrence A Leiter,[...]. JAMA Cardiol 2021
6

The impact of diabetes on heart failure development: The cardio-renal-metabolic connection.
Paul Valensi, Gaétan Prévost, Sara Pinto, Jean-Michel Halimi, Erwan Donal. Diabetes Res Clin Pract 2021
0

Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.
Gad Cotter, Beth A Davison, Christopher Edwards, Stefanie Senger, John R Teerlink, Faiez Zannad, Olav Wendelboe Nielsen, Marco Metra, Alexandre Mebazaa, Ovidiu Chioncel,[...]. Am Heart J 2021
0

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
William G Herrington, Gianluigi Savarese, Richard Haynes, Nikolaus Marx, Linda Mellbin, Lars H Lund, Paul Dendale, Petar Seferovic, Giuseppe Rosano, Natalie Staplin,[...]. Eur J Heart Fail 2021
8

How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR.
Clara García-Carro, Ander Vergara, Sheila Bermejo, María A Azancot, Ana I Sánchez-Fructuoso, M Dolores Sánchez de la Nieta, Irene Agraz, María José Soler. J Clin Med 2021
3

Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review.
Roy Rasalam, John J Atherton, Gary Deed, Michael Molloy-Bland, Neale Cohen, Andrew Sindone. ESC Heart Fail 2021
2


Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials.
Li-Min Zhao, Jia-Nan Huang, Mei Qiu, Liang-Liang Ding, Ze-Lin Zhan, Jie Ning. Medicine (Baltimore) 2021
1

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials.
Natalie Staplin, Alistair J Roddick, Jonathan Emberson, Christina Reith, Alex Riding, Alexa Wonnacott, Apexa Kuverji, Sunil Bhandari, Colin Baigent, Richard Haynes,[...]. EClinicalMedicine 2021
1

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs.
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Maria Ida Maiorino, Katherine Esposito. Cardiovasc Diabetol 2021
5

Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium.
Winde Jorissen, Lieven Annemans, Nicolas Louis, Andreas Nilsson, Michael Willis. Acta Clin Belg 2021
0